Perampanel
chemical compound
Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai that is used in addition to other medications to treat partial seizures and generalized tonic–clonic seizures.
Perampanel is a non-competitive AMPA glutamate receptor antagonist. It is taken by mouth.
Perampanel was approved in 2012, and as of 2016, its optimal role in the treatment of epilepsy relative to other drugs is not clear. It is the first anti-epileptic drug in the class of selective non-competitive antagonist of AMPA receptors.
The US prescribing information has a boxed warning that perampanel may cause serious psychiatric and behavioral changes; it may cause homicidal or suicidal thoughts. Other side effects have included dizziness, somnolence, vertigo, aggression, anger, loss of coordination, blurred vision, irritability, and slurred speech. Perampanel reduced the effectiveness of levonorgestrel oral contraceptives by about 40%. Women who may get pregnant should not take it as studies in animals show it may harm a fetus. Perampanel is liable to be abused; very high doses produced euphoria responses similar to ketamine.
“Perampanel” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Perampanel, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Perampanel” is worth following because a concise public description often conceals a longer documentary argument. Here, Perampanel, chemical and compound provides the most credible route into that argument.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Sep 5, 2026. The linked authority identifier is Q868658. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2012 and 2016.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Perampanel”, its source revision and the description used here.
- Expand the search: follow Perampanel primary sources, Perampanel archive and Perampanel research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Perampanel”?
- Is the terminology current, historical or disputed?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Perampanel” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.